Biocryst Pharmaceuticals Stock In The News
| BCRX Stock | USD 7.54 0.17 2.20% |
Our overall analysis of BioCryst Pharmaceuticals' news coverage and content from conventional and social sources shows investors' bearish mood towards BioCryst Pharmaceuticals. The specific impact of BioCryst Pharmaceuticals news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of BioCryst Pharmaceuticals' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using BioCryst Pharmaceuticals headlines in addition to utilizing other, more conventional financial analysis modules. Check out BioCryst Pharmaceuticals Backtesting and BioCryst Pharmaceuticals Hype Analysis. For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.
BioCryst |
BioCryst Pharmaceuticals Today Top News and Investor Outlook
BioCryst Pharmaceuticals Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide BioCryst and other traded companies coverage with news coverage. We help investors stay connected with BioCryst headlines for the 14th of March 2025 to make an informed investment decision based on correlating the impacts of news items on BioCryst Stock performance. Please note that trading solely based on the BioCryst Pharmaceuticals hype is not for everyone as timely availability and quick action are needed to avoid losses.
BioCryst Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the BioCryst earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about BioCryst Pharmaceuticals that are available to investors today. That information is available publicly through BioCryst media outlets and privately through word of mouth or via BioCryst internal channels. However, regardless of the origin, that massive amount of BioCryst data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of BioCryst Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of BioCryst Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to BioCryst Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive BioCryst Pharmaceuticals alpha.
BioCryst Largest EPS Surprises
Earnings surprises can significantly impact BioCryst Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-04 | 2024-09-30 | -0.06 | -0.07 | -0.01 | 16 | ||
2017-08-07 | 2017-06-30 | -0.19 | -0.21 | -0.02 | 10 | ||
2013-02-19 | 2012-12-31 | -0.16 | -0.18 | -0.02 | 12 | ||
2004-02-04 | 2003-12-31 | -0.2 | -0.18 | 0.02 | 10 | ||
2000-10-25 | 2000-09-30 | -0.11 | -0.09 | 0.02 | 18 | ||
2000-02-02 | 1999-12-31 | -0.01 | -0.03 | -0.02 | 200 |
BioCryst Pharmaceuticals Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to BioCryst Pharmaceuticals Stock. Current markets are slightly bearish. About 51% of major world exchanges and indexes are down. See today's market update for more information.
6th of March 2025
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635 at gurufocus.com
4th of March 2025
BioCryst falls 8 percent following CFO departure announcement at seekingalpha.com
28th of February 2025
Acquisition by Milano Vincent of 653 shares of BioCryst Pharmaceuticals at 8.61 subject to... at MacroaxisInsider
26th of February 2025
Heres Why BioCryst Could be Great Choice for a Bottom Fisher at finance.yahoo.com
25th of February 2025
BioCryst Pharmaceuticals, Inc. Q4 2024 Earnings Call Transcript at insidermonkey.com
24th of February 2025
BioCryst Stock Drops on Earnings and Mixed Guidance at gurufocus.com
21st of February 2025
Amneal Pharmaceuticals Reports Next Week Wall Street Expects Earnings Growth at finance.yahoo.com
3rd of February 2025
BioCryst Pharmaceuticals, Inc. Sees Significant Decrease in Short Interest at thelincolnianonline.com
6th of January 2025
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635 at globenewswire.com
BioCryst Pharmaceuticals Investors Sentiment
The influence of BioCryst Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in BioCryst. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to BioCryst Pharmaceuticals' public news can be used to forecast risks associated with an investment in BioCryst. The trend in average sentiment can be used to explain how an investor holding BioCryst can time the market purely based on public headlines and social activities around BioCryst Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
BioCryst Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for BioCryst Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average BioCryst Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on BioCryst Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards BioCryst Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, BioCryst Pharmaceuticals' short interest history, or implied volatility extrapolated from BioCryst Pharmaceuticals options trading.
Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.